Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights in this issue include a feature on new momentum to end the AIDS epidemic in light of the new HPTN 052 results showing that early ARV treatment is highly protective against transmitting HIV to one’s sexual partner. This issue also includes an abbreviated roadmap highlighting sessions on the latest biomedical prevention updates at the upcoming 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. As appears each quarter, this issue includes a center foldout poster with an updated comprehensive timeline of efficacy trials of new biomedical HIV prevention worldwide and a world map showing where various strategies are being tested.
Px Wire April-June 2011, Vol. 4, No. 2
Px Wire October-December 2010, Vol. 3, No. 4
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. Highlights in this issue include an update of the ongoing discussions around the follow-up of the CAPRISA 004 trial finding that 1% tenofovir gel reduces a women’s risk of acquiring HIV by 39 percent overall and asks follow-up questions. What additional trials are being considered and why? Who will map the next steps? This issue also touches on the increasing discussions of “treatment as prevention” in reference to the possible use of antiretroviral treatment to reduce the risk of HIV transmission.
Comment Letter to Ambassador Goosby on Draft PEPFAR Country Operational Plan for Zimbabwe
A 4-page response letter developed by a coalition of civil society groups summarizing concerns and demands related to the US PEPFAR program’s 2012 Country Operating Plan. A country operating plan dictates the scope, funding levels and targets of PEPFAR programming on an annual basis.
Px Wire July-September 2010, Vol. 3, No. 3
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue reviews highlights from the biannual International Microbicides Conference (M2010) held in May, including discussions of the potential opportunities and challenges of ARV-based prevention in topical and oral forms, new developments in delivery systems for microbicides and increasing recognition of rectal microbicides as a key area for exploration. This issue also covers what to expect with the forthcoming results of CAPRISA 004.
Px Wire July-September 2009, Vol. 2, No. 3
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue is designed to provide background and perspectives on some of the key issues and questions that have emerged as work around understanding and interpreting the results of the Thai trial moves forward.
Px Wire April-June 2009, Vol. 2, No. 2
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue features multiple trial updates, including a review of the key findings from a trial of HSV-2 suppression. The issue also features a discussion of the results of the HPTN 035 microbicide trial (which tested PRO 2000 and BufferGel) and preparations for the upcoming results of MDP 301, also testing PRO 2000 gel. Additionally, this issue provides information on new trials including HVTN 505 (described in this year’s first issue of Px Wire), which began screening participants in June, a new trial on intermittent PrEP scheduled to begin in July, and research to test a nipple shield to help prevent HIV transmission during breastfeeding.
Px Wire April-June 2014, Vol. 7, No. 2
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue reviews the research on long-acting injectable antiretrovirals for treatment in HIV-positive people and PrEP in HIV-negative people and also explores progress in implementing oral PrEP in the nearly 24 months since the US Food and Drug Administration approved daily oral TDF/FTC (Truvada) as PrEP.
Px Wire January-March 2014, Vol. 7, No. 1
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. In this issue of Px Wire, AVAC applauds the nomination of Dr. Debbi Birx as the new US Global AIDS Coordinator. Highlights of this issue also include an examination of why the global systems for tracking voluntary medical male circumcision are lagging behind the actual progress that’s being made—and discusses ways to close this critical data gap. This issue also reviews a recent setback in cure research and what it means for next steps.
Px Wire October-December 2013, Vol. 6, No. 4
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue reports on a recent think tank meeting on therapeutic HIV vaccines—these vaccines would attempt to control or eliminate the virus by prompting immune responses in HIV-positive people. Also in this issue is a brief report on the recent NIAID “mini-summit” on adenovirus platforms for HIV vaccines.
Px Wire July-September 2013, Vol. 6, No. 3
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This quarter, Px Wire highlights three recent developments in the field and key issues for each: the World Health Organization (WHO) prequalification of PrePex, a nonsurgical voluntary medical male circumcision device; the positive result from the study of daily oral tenofovir as PrEP for HIV prevention in people who inject drugs; and new WHO guidelines on the use of ARVs, which recommend antiretroviral treatment for all HIV-positive people with CD4 cell counts of 500 or below.